GlassScriptPhysician profile
Alyssa Ann Tobe
NPI 1942542170
$589.81
in general payments reported to CMS, 2019-2025
14 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.36 · 2022: $43.29 · 2023: $165 · 2024: $205 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $130.19 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $83.97 | 2024 | Repatha, Otezla, Prolia |
| Abbvie INC. | $59.82 | 2023-2024 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $55.20 | 2023-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $53.50 | 2023-2025 | Freestyle Libre 3 |
| Insulet Corporation | $34.11 | 2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $33.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.18 | 2022 | |
| Lilly USA, LLC | $30.58 | 2023-2024 | Mounjaro |
| Pfizer INC. | $19.06 | 2023 | |
| Medtronic, INC. | $15.52 | 2025 | Kyphon Express II Kyphopak Tray |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.02 | 2023 | Jardiance |
| Exact Sciences Corporation | $14.66 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $13.64 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Tobe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.